NHIA to assess paying hefty price for new hemophilia B gene therapy

The National Health Insurance Administration (NHIA) will evaluate including a one-time gene therapy to treat individuals with hemophilia B in the NHI drug reimbursement scheme after it is approved in Taiwan, an NHIA official said Monday.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)